Celiac disease affects approximately 1 percent of the global population, an estimated 2 million Americans, yet only about 30 percent are correctly diagnosed. The average delay between symptom onset and confirmed diagnosis has historically been 6 to 10 years, during which the autoimmune damage to the small intestine accumulates silently. People with undiagnosed celiac disease face a 2-fold greater risk of coronary artery disease, a 4-fold greater risk of small bowel cancers, and significantly elevated risks of osteoporosis, infertility, and type 1 diabetes.
Unlike food intolerances or wheat allergies, celiac disease is an autoimmune condition. There is no dose threshold below which intestinal damage does not occur, any gluten exposure activates the immune cascade. Yet the FDA's gluten-free labeling rule, which was designed to protect celiac patients, was set at a threshold determined by what analytical equipment could reliably detect, not by what is definitively safe for all individuals.
This guide covers the disease mechanism, the regulatory framework, every hidden gluten source, and the certification seals that go beyond FDA's 20 ppm standard.





